Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 106 | Mundipharma Research LimitedINDUSTRY | 7 | Jul 25, 2024 | clinicaltrials |
| NCT02920697 | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 65 | Institut de Recherches Internationales ServierOTHER | 8 | Jul 25, 2024 |
| clinicaltrials |
| NCT04555811 | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | completed | Phase 1 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04434469 | A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 27 | Genentech, Inc.INDUSTRY | 4 | Jul 3, 2024 | clinicaltrials |
| NCT05679258 | A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects | completed | Phase 1 | 172 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02631044 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | completed | Phase 1 | 387 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT03309111 | Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma | completed | Phase 1 | 81 | Ichnos Sciences SAINDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT04279405 | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies | completed | Phase 1 | 43 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03061188 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | completed | Phase 1 | 15 | Northwestern UniversityOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | completed | Phase 1 | 70 | Sutro Biopharma, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma(ZUMA-1) | completed | Phase 1 / Phase 2 | 307 | Kite, A Gilead CompanyINDUSTRY | 6 | Jun 4, 2024 | clinicaltrials |
| NCT02184533 | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | 15 | Stanford UniversityOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03143985 | Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 18 | Koen van BesienOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03430011 | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma(EVOLVE) | completed | Phase 1 / Phase 2 | 165 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT04231747 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 | 24 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 2 | May 20, 2024 | clinicaltrials |
| NCT02101944 | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | May 17, 2024 | clinicaltrials |
| NCT02697383 | Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study | completed | Phase 1 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT03892044 | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | completed | Phase 1 | 7 | David Bond, MDOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT00457782 | A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 27 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT00888927 | Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT01063907 | A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 95 | Kyowa Kirin Co., Ltd.INDUSTRY | 3 | Apr 25, 2024 | clinicaltrials |
| NCT02157636 | A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma | completed | Phase 1 | 30 | Constellation PharmaceuticalsINDUSTRY | 0 | Apr 18, 2024 | clinicaltrials |
| NCT03246750 | B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma | completed | Phase 1 / Phase 2 | 34 | The Thai Lymphoma Study GroupOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03610061 | A Trial of Radiotherapy and Durvalumab in DLBCL and FL(RaDD) | completed | Phase 1 | 34 | Austin HealthOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03848845 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 4) | completed | Phase 1 / Phase 2 | 41 | GlaxoSmithKlineINDUSTRY | 4 | Apr 9, 2024 | clinicaltrials |
| NCT02341014 | Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas | completed | Phase 1 / Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03310619 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies(PLATFORM) | completed | Phase 1 / Phase 2 | 62 | CelgeneINDUSTRY | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03722147 | A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 94 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT02812706 | Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients(Islands) | completed | Phase 1 / Phase 2 | 36 | SanofiINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05321147 | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | completed | Phase 1 | 20 | Innate PharmaINDUSTRY | 2 | Mar 28, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT03056339 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT02119468 | Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03311828 | Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04557436 | TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)(PBLTT52CAR19) | completed | Phase 1 | 9 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02926833 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(ZUMA-6) | completed | Phase 1 / Phase 2 | 37 | Kite, A Gilead CompanyINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04671251 | Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 13 | Avalo Therapeutics, Inc.INDUSTRY | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03013933 | Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 | 29 | City of Hope Medical CenterOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT02056756 | Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Stichting European Myeloma NetworkNETWORK | 2 | Feb 20, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01995708 | CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | completed | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02561962 | A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 42 | AmgenINDUSTRY | 2 | Feb 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 25, 2024source: clinicaltrials